Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is an experimental small molecule with the chemical formula C22H23F2N7O and a molecular weight of approximately 439.46 g/mol. It contains structural motifs including a difluorinated ethyl group attached to a piperidine ring and an oxazolo[4,5-c]pyridine core substituted with both triazole and benzyl groups. There is no evidence of clinical development or approved therapeutic use for this molecule as of now. Its mechanism of action and biological targets are not described in public databases; it appears to be primarily referenced in chemical structure repositories as an experimental or research compound rather than as an active pharmaceutical ingredient.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-{2,2-difluoro-2-[(2R)-piperidin-2-yl]ethyl}-2-[2-(1H-1,2,4-triazol-1-yl)benzyl][1,3]oxazolo[4,5-c]pyridin-4-amine.